Breast Cancer, Cancer Survivor, Hot Flashes
Conditions
Keywords
hot flashes, cancer survivor, breast cancer
Brief summary
RATIONALE: Magnesium oxide may help relieve hot flashes symptoms in women with a history of breast cancer. PURPOSE: This randomized clinical trial studies how well a high-dose or a low-dose of magnesium oxide works compared to placebo in treating menopausal women with hot flashes and a history of breast cancer.
Detailed description
OBJECTIVES: Primary * Evaluate the efficacy of magnesium oxide on hot flashes in women with a history of breast cancer. Secondary * Evaluate the side-effect profile of magnesium oxide in this study population. * Evaluate the effect of magnesium oxide on the secondary outcomes hot flash frequencies, hot flash severities, toxicities (including diarrhea), and hot flash-related daily interference on activities. * Evaluate the effect of magnesium oxide on the change of magnesium level (for the first 150 patients). OUTLINE: This is a multicenter study. Patients are stratified according to age (18-49 years vs ≥ 50 years), current tamoxifen and/or selective estrogen receptor modulator (yes vs no), current aromatase inhibitor (yes vs no), and daily frequency of hot flashes (4-9 vs ≥ 10). Patients are randomized to 1 of 4 treatment arms. * Arm I: Patients receive a low-dose of magnesium oxide orally (PO) daily (QD). * Arm II: Patients receive a high-dose of magnesium oxide PO QD. * Arm III: Patients receive a low-dose of placebo PO QD. * Arm IV: Patients receive a high-dose of placebo PO QD. In all arms, treatment continues for 8 weeks in the absence of unacceptable toxicity. Some patients may continue or crossover to receive magnesium for 4 more weeks. Patients complete the Hot Flash Diary daily for 9 weeks beginning 1 week before treatment. They also complete the Symptom Experience Questionnaire, the Profile of Mood States (POMS), and Hot Flash-Related Daily Interference Scale (HFRDIS) questionnaires periodically during study treatment. Patients undergo blood sample collection at baseline and at the end of weeks 5 and 9 for serum magnesium level analysis.
Interventions
DRUGmagnesium oxide
Given PO
OTHERplacebo
Given PO
Sponsors
National Cancer Institute (NCI)
Alliance for Clinical Trials in Oncology
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
DISEASE CHARACTERISTICS: * Women with a history of breast cancer (currently without malignant disease) * Bothersome hot flashes (defined by their occurrence ≥ 28 times per week and of sufficient severity to make the patient desire therapeutic intervention) * Presence of hot flashes for ≥ 30 days prior to study registration * Willingness to provide the biologic specimens as required by the protocol * Hormone receptor status not specified PATIENT CHARACTERISTICS: * Women who are postmenopausal as defined by absence of a period in the past 12 months or bilateral oophorectomy * Women with at least one ovary but without a uterus should be deemed postmenopausal by either age over 55 or a combination of estrogen within a postmenopausal range (per local lab) and FSH over 40 mIU/mL * No women of childbearing potential or who are premenopausal * Creatinine clearance \> 30 mL/min * Ability to complete questionnaire(s) by themselves or with assistance * ECOG performance status 0 or 1 * No history of allergic or other adverse reaction to magnesium * No diabetes * No patients with conditions that are implicated in decreased absorption of magnesium (e.g., Crohn disease, ETOH abuse) * No patients who have diarrhea where magnesium might make it worse (per provider discretion) PRIOR CONCURRENT THERAPY: * None of the following current (≤ 28 days prior to registration) or planned therapies (tamoxifen, raloxifene, or aromatase inhibitors are allowed, but the patient must have been on a constant dose for ≥ 28 days and must not be expected to stop the medication during the study period): * Antineoplastic chemotherapy (trastuzumab or lapatinib are allowed) * Androgens * Estrogens (any delivery route) * Progestational agents * No prior use of magnesium for hot flashes * No current or planned use of gabapentin (for any reasons) or antidepressants (for any reasons) or other agents for treating hot flashes (except stable dose of vitamin E is allowed as long as it was started \> 30 days prior to study registration and are to be continued through the study period; soy is allowed, if it is planned to be continued at the same dose during the study period) * No current use of magnesium for any indication (except one standard multiple vitamin dose is allowed per day) * Not taking diuretics, corticosteroids, bile acid sequestrants, and other prescription and over-the-counter medications that may affect magnesium levels * No current (≤ 7 days prior to registration) or planned use of other non-drug therapies for managing hot flashes, such as acupuncture or yoga (use of these therapies for other reasons is allowed)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The Intra-patient Changes of Weekly Hot Flash Activity From Baseline During the Treatment Period. | Baseline to Week 8 | The primary endpoint is the intra-patient changes of weekly hot flash activity from baseline during the treatment period. The hot flash activity will be measured by the weekly average hot flash score, which is a composite entity of both frequency and severity of hot flashes. The hot flash severity is graded from 1 to 4 (1=mild, 2=moderate, 3=severe, and 4=very severe). The daily hot flash score is computed by multiplying the mean grade of severity by the frequency during every 24 hour period. Therefore, a score of zero is the lowest possible score and can be interpreted as having no hot flashes. The weekly hot flash score was calculated by adding all scores for the week. The mean Hot Flash Score for each week for each group is reported and a repeated measures analysis is reported comparing each dose level group to the Placebo group. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Weekly Frequency of Hot Flashes as Measured by the Hot Flash Diary During the Treatment Period | Baseline to Week 8 | As part of the Hot Flash Diary, the number of hot flashes was recorded for each patient for each week. For this endpoint, the mean number of hot flashes for each group is reported. A repeated measure analysis comparing each dose level group and the Placebo is reported. |
| Frequency and Maximum Grade of Adverse Events Reported Via the CTCAE 4.0 During the Treatment Period. | Baseline to Week 8 | Frequency and severity of adverse events reported by patients in weekly Symptom Experience Questionnaire and evaluated through clinical assessment by NCI CTCAE v3.0. The number of patients reporting grade 3 or higher events are reported in this outcome measure. For a full list of all events, please refer to the Adverse Events section of this report. |
| The Change of Severity of Symptoms as Measured the Symptom Experience Questionnaire From Baseline to Treatment Termination | Baseline to week 8 | We will use the Symptom Experience Questionnaire (SEQ) to evaluate the specific impact of the study treatment on the effect hot flashes have on various life activities such as work, social, leisure and relationships. The questionnaire is 14 questions and is based on a 0=Not at all to 10=As bad as it can be scale. The change of severity of symptoms as measured by the SEQ from baseline to treatment termination will be first summarized by descriptive statistics as a percent change from baseline. |
| The Change of Daily Interference as Measured by the Hot Flash Related Daily Interference Scale (HFRDIS) From Baseline to Treatment Termination. | Baseline to week 8 | We will use the Hot Flash Related Daily Interference Scale (HFRDIS) (SEQ) to evaluate the specific effect of hot flashes have on various life activities such as work, social, leisure and relationships while receiving treatment. The questionnaire is 10 questions and is based on a 0=Do not interfere to 10=Completely interfere scale. The weekly score is the summation of these 10 questions and therefore ranges from 0 to 100. The total change in severity of symptoms is calculated by subtracting the week 8 score from the baseline. Therefore, values below zero indicate a worsening of symptoms and values above zero indicate an improvement and has a maximum range of -100 to 100. A gatekeeper procedure, following a fixed-sequence hypothesis testing method, was used to examine the higher dose of magnesium vs. placebo first and then the lower dose of magnesium vs. placebo, if the former was statistically significant. |
| The Intra-patient Changes of Magnesium Level From Baseline to the End of Treatment Period Between Magnesium Oxide and Placebo Arms. | Baseline to week 8 | The intra-patient changes of magnesium level from baseline to the end of treatment period between magnesium oxide and placebo arms will be compared using a repeated measures model. Serum magnesium concentrations will be performed prior to study medication usage and during the last week of blinded study use. These will be obtained in the first 150 patients. Mean change in serum magnesium concentrations will be compared between the 3 study arms to determine whether there are any apparent changes in the patients receiving placebos vs the two magnesium doses. |
Countries
United States
Participant flow
Pre-assignment details
After the double blind phase patient were allowed to re-registered on the Optional Continuation Phase of the study. This phase lasted up to 4 weeks of treatment following either 800 or 1200 mg/day treatment group.
Participants by arm
| Arm | Count |
|---|---|
| Low Dose Magnesium Oxide (800 mg/Day) Week 2:
Patients take one 400 mg tablet of magnesium oxide orally (PO) daily (QD).
Week 3:
Patients take two 400 mg tablet of magnesium oxide orally (PO) daily (QD).
Weeks 4-9:
Patients take two 400 mg tablet of magnesium oxide orally (PO) daily (QD). | 93 |
| High Dose Magnesium Oxide (1200 mg/Day) Week 2:
Patients take one 400 mg tablet of magnesium oxide orally (PO) daily (QD).
Week 3:
Patients take two 400 mg tablet of magnesium oxide orally (PO) daily (QD).
Weeks 4-9:
Patients take three 400 mg tablet of magnesium oxide orally (PO) daily (QD). | 91 |
| Placebo Patients registered to the High Dose Placebo and Low Dose Placebo are combined for treatment analysis.
Week 2:
Patients take one placebo tablets orally (PO) daily (QD).
Week 3:
Patients take two placebo tablets daily (QD).
Weeks 4-9:
Patients take two or three placebo tablets daily (QD). | 91 |
| Total | 275 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 |
|---|---|---|---|---|---|
| Double-Blind Treatment Phase | Ineligible | 1 | 2 | 0 | 1 |
| Double-Blind Treatment Phase | Withdrawal by Subject | 3 | 3 | 3 | 1 |
Baseline characteristics
| Characteristic | Low Dose Magnesium Oxide (800 mg/Day) | High Dose Magnesium Oxide (1200 mg/Day) | Placebo | Total |
|---|---|---|---|---|
| Age, Customized Age Group 18-49 years | 15 Participants | 15 Participants | 15 Participants | 45 Participants |
| Age, Customized Age Group >=50 | 78 Participants | 76 Participants | 76 Participants | 230 Participants |
| Region of Enrollment United States | 93 participants | 91 participants | 91 participants | 275 participants |
| Sex: Female, Male Female | 93 Participants | 91 Participants | 91 Participants | 275 Participants |
| Sex: Female, Male Male | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk |
|---|---|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — | — / — | — / — |
| other Total, other adverse events | 67 / 92 | 40 / 93 | 31 / 92 | 40 / 116 |
| serious Total, serious adverse events | 0 / 92 | 1 / 93 | 0 / 92 | 0 / 116 |
Outcome results
Primary
The Intra-patient Changes of Weekly Hot Flash Activity From Baseline During the Treatment Period.
The primary endpoint is the intra-patient changes of weekly hot flash activity from baseline during the treatment period. The hot flash activity will be measured by the weekly average hot flash score, which is a composite entity of both frequency and severity of hot flashes. The hot flash severity is graded from 1 to 4 (1=mild, 2=moderate, 3=severe, and 4=very severe). The daily hot flash score is computed by multiplying the mean grade of severity by the frequency during every 24 hour period. Therefore, a score of zero is the lowest possible score and can be interpreted as having no hot flashes. The weekly hot flash score was calculated by adding all scores for the week. The mean Hot Flash Score for each week for each group is reported and a repeated measures analysis is reported comparing each dose level group to the Placebo group.
Time frame: Baseline to Week 8
Population: All patients that began protocol treatment and completed the Hot Flash Diary were included in this analysis.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Low Dose Magnesium Oxide (800 mg/Day) | The Intra-patient Changes of Weekly Hot Flash Activity From Baseline During the Treatment Period. | Week 3 | 12.29 units on a scale | Standard Deviation 9.79 |
| Low Dose Magnesium Oxide (800 mg/Day) | The Intra-patient Changes of Weekly Hot Flash Activity From Baseline During the Treatment Period. | Week 8 | 12.17 units on a scale | Standard Deviation 10.88 |
| Low Dose Magnesium Oxide (800 mg/Day) | The Intra-patient Changes of Weekly Hot Flash Activity From Baseline During the Treatment Period. | Week 5 | 11.77 units on a scale | Standard Deviation 10.86 |
| Low Dose Magnesium Oxide (800 mg/Day) | The Intra-patient Changes of Weekly Hot Flash Activity From Baseline During the Treatment Period. | Week 4 | 11.73 units on a scale | Standard Deviation 10.35 |
| Low Dose Magnesium Oxide (800 mg/Day) | The Intra-patient Changes of Weekly Hot Flash Activity From Baseline During the Treatment Period. | Baseline | 16.02 units on a scale | Standard Deviation 9.62 |
| Low Dose Magnesium Oxide (800 mg/Day) | The Intra-patient Changes of Weekly Hot Flash Activity From Baseline During the Treatment Period. | Week 7 | 11.92 units on a scale | Standard Deviation 11.26 |
| Low Dose Magnesium Oxide (800 mg/Day) | The Intra-patient Changes of Weekly Hot Flash Activity From Baseline During the Treatment Period. | Week 2 | 12.68 units on a scale | Standard Deviation 8.87 |
| Low Dose Magnesium Oxide (800 mg/Day) | The Intra-patient Changes of Weekly Hot Flash Activity From Baseline During the Treatment Period. | Week 1 | 14.28 units on a scale | Standard Deviation 9.26 |
| Low Dose Magnesium Oxide (800 mg/Day) | The Intra-patient Changes of Weekly Hot Flash Activity From Baseline During the Treatment Period. | Week 6 | 11.61 units on a scale | Standard Deviation 10.46 |
| High Dose Magnesium Oxide (1200 mg/Day) | The Intra-patient Changes of Weekly Hot Flash Activity From Baseline During the Treatment Period. | Week 4 | 10.14 units on a scale | Standard Deviation 8.61 |
| High Dose Magnesium Oxide (1200 mg/Day) | The Intra-patient Changes of Weekly Hot Flash Activity From Baseline During the Treatment Period. | Baseline | 15.35 units on a scale | Standard Deviation 10.53 |
| High Dose Magnesium Oxide (1200 mg/Day) | The Intra-patient Changes of Weekly Hot Flash Activity From Baseline During the Treatment Period. | Week 1 | 14.47 units on a scale | Standard Deviation 11.1 |
| High Dose Magnesium Oxide (1200 mg/Day) | The Intra-patient Changes of Weekly Hot Flash Activity From Baseline During the Treatment Period. | Week 2 | 12.59 units on a scale | Standard Deviation 10.01 |
| High Dose Magnesium Oxide (1200 mg/Day) | The Intra-patient Changes of Weekly Hot Flash Activity From Baseline During the Treatment Period. | Week 3 | 11.32 units on a scale | Standard Deviation 10.72 |
| High Dose Magnesium Oxide (1200 mg/Day) | The Intra-patient Changes of Weekly Hot Flash Activity From Baseline During the Treatment Period. | Week 5 | 9.73 units on a scale | Standard Deviation 9.19 |
| High Dose Magnesium Oxide (1200 mg/Day) | The Intra-patient Changes of Weekly Hot Flash Activity From Baseline During the Treatment Period. | Week 6 | 9.44 units on a scale | Standard Deviation 8.99 |
| High Dose Magnesium Oxide (1200 mg/Day) | The Intra-patient Changes of Weekly Hot Flash Activity From Baseline During the Treatment Period. | Week 7 | 9.37 units on a scale | Standard Deviation 9.24 |
| High Dose Magnesium Oxide (1200 mg/Day) | The Intra-patient Changes of Weekly Hot Flash Activity From Baseline During the Treatment Period. | Week 8 | 9.06 units on a scale | Standard Deviation 8.87 |
| Placebo | The Intra-patient Changes of Weekly Hot Flash Activity From Baseline During the Treatment Period. | Week 2 | 13.29 units on a scale | Standard Deviation 9.46 |
| Placebo | The Intra-patient Changes of Weekly Hot Flash Activity From Baseline During the Treatment Period. | Baseline | 17.28 units on a scale | Standard Deviation 10.84 |
| Placebo | The Intra-patient Changes of Weekly Hot Flash Activity From Baseline During the Treatment Period. | Week 6 | 11.17 units on a scale | Standard Deviation 8.78 |
| Placebo | The Intra-patient Changes of Weekly Hot Flash Activity From Baseline During the Treatment Period. | Week 1 | 15.52 units on a scale | Standard Deviation 10.51 |
| Placebo | The Intra-patient Changes of Weekly Hot Flash Activity From Baseline During the Treatment Period. | Week 8 | 11.42 units on a scale | Standard Deviation 10.32 |
| Placebo | The Intra-patient Changes of Weekly Hot Flash Activity From Baseline During the Treatment Period. | Week 4 | 12.02 units on a scale | Standard Deviation 9.57 |
| Placebo | The Intra-patient Changes of Weekly Hot Flash Activity From Baseline During the Treatment Period. | Week 3 | 12.34 units on a scale | Standard Deviation 9.98 |
| Placebo | The Intra-patient Changes of Weekly Hot Flash Activity From Baseline During the Treatment Period. | Week 7 | 10.71 units on a scale | Standard Deviation 8.68 |
| Placebo | The Intra-patient Changes of Weekly Hot Flash Activity From Baseline During the Treatment Period. | Week 5 | 11.63 units on a scale | Standard Deviation 9.61 |
p-value: 0.13ANOVA
p-value: 0.67ANOVA
Secondary
Frequency and Maximum Grade of Adverse Events Reported Via the CTCAE 4.0 During the Treatment Period.
Frequency and severity of adverse events reported by patients in weekly Symptom Experience Questionnaire and evaluated through clinical assessment by NCI CTCAE v3.0. The number of patients reporting grade 3 or higher events are reported in this outcome measure. For a full list of all events, please refer to the Adverse Events section of this report.
Time frame: Baseline to Week 8
Population: All patients that started protocol treatment and were evaluated for adverse events are included in this analysis.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Low Dose Magnesium Oxide (800 mg/Day) | Frequency and Maximum Grade of Adverse Events Reported Via the CTCAE 4.0 During the Treatment Period. | Grade 3+ Adverse Event | 5 Participants |
| Low Dose Magnesium Oxide (800 mg/Day) | Frequency and Maximum Grade of Adverse Events Reported Via the CTCAE 4.0 During the Treatment Period. | Grade 4+ Adverse Event | 0 Participants |
| High Dose Magnesium Oxide (1200 mg/Day) | Frequency and Maximum Grade of Adverse Events Reported Via the CTCAE 4.0 During the Treatment Period. | Grade 3+ Adverse Event | 1 Participants |
| High Dose Magnesium Oxide (1200 mg/Day) | Frequency and Maximum Grade of Adverse Events Reported Via the CTCAE 4.0 During the Treatment Period. | Grade 4+ Adverse Event | 0 Participants |
| Placebo | Frequency and Maximum Grade of Adverse Events Reported Via the CTCAE 4.0 During the Treatment Period. | Grade 3+ Adverse Event | 2 Participants |
| Placebo | Frequency and Maximum Grade of Adverse Events Reported Via the CTCAE 4.0 During the Treatment Period. | Grade 4+ Adverse Event | 0 Participants |
Secondary
The Change of Daily Interference as Measured by the Hot Flash Related Daily Interference Scale (HFRDIS) From Baseline to Treatment Termination.
We will use the Hot Flash Related Daily Interference Scale (HFRDIS) (SEQ) to evaluate the specific effect of hot flashes have on various life activities such as work, social, leisure and relationships while receiving treatment. The questionnaire is 10 questions and is based on a 0=Do not interfere to 10=Completely interfere scale. The weekly score is the summation of these 10 questions and therefore ranges from 0 to 100. The total change in severity of symptoms is calculated by subtracting the week 8 score from the baseline. Therefore, values below zero indicate a worsening of symptoms and values above zero indicate an improvement and has a maximum range of -100 to 100. A gatekeeper procedure, following a fixed-sequence hypothesis testing method, was used to examine the higher dose of magnesium vs. placebo first and then the lower dose of magnesium vs. placebo, if the former was statistically significant.
Time frame: Baseline to week 8
Population: All patients that began treatment and completed the HFRDI questionnaire at baseline and week 8 were used in this analysis.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Low Dose Magnesium Oxide (800 mg/Day) | The Change of Daily Interference as Measured by the Hot Flash Related Daily Interference Scale (HFRDIS) From Baseline to Treatment Termination. | 7 units on a scale |
| High Dose Magnesium Oxide (1200 mg/Day) | The Change of Daily Interference as Measured by the Hot Flash Related Daily Interference Scale (HFRDIS) From Baseline to Treatment Termination. | 8.5 units on a scale |
p-value: 1Wilcoxon (Mann-Whitney)
Secondary
The Change of Severity of Symptoms as Measured the Symptom Experience Questionnaire From Baseline to Treatment Termination
We will use the Symptom Experience Questionnaire (SEQ) to evaluate the specific impact of the study treatment on the effect hot flashes have on various life activities such as work, social, leisure and relationships. The questionnaire is 14 questions and is based on a 0=Not at all to 10=As bad as it can be scale. The change of severity of symptoms as measured by the SEQ from baseline to treatment termination will be first summarized by descriptive statistics as a percent change from baseline.
Time frame: Baseline to week 8
Population: All patients that started treatment and completed the Symptom Experience Questionnaire at baseline and Cycle 9 were included in this analysis.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Low Dose Magnesium Oxide (800 mg/Day) | The Change of Severity of Symptoms as Measured the Symptom Experience Questionnaire From Baseline to Treatment Termination | Trouble Sleeping | 10 percentage change |
| Low Dose Magnesium Oxide (800 mg/Day) | The Change of Severity of Symptoms as Measured the Symptom Experience Questionnaire From Baseline to Treatment Termination | Fatigue | 0 percentage change |
| Low Dose Magnesium Oxide (800 mg/Day) | The Change of Severity of Symptoms as Measured the Symptom Experience Questionnaire From Baseline to Treatment Termination | Nausea | 0 percentage change |
| Low Dose Magnesium Oxide (800 mg/Day) | The Change of Severity of Symptoms as Measured the Symptom Experience Questionnaire From Baseline to Treatment Termination | Muscle/Joint Aches | 5 percentage change |
| Low Dose Magnesium Oxide (800 mg/Day) | The Change of Severity of Symptoms as Measured the Symptom Experience Questionnaire From Baseline to Treatment Termination | Muscle Weakness | 0 percentage change |
| Low Dose Magnesium Oxide (800 mg/Day) | The Change of Severity of Symptoms as Measured the Symptom Experience Questionnaire From Baseline to Treatment Termination | Diarrhea | 0 percentage change |
| Low Dose Magnesium Oxide (800 mg/Day) | The Change of Severity of Symptoms as Measured the Symptom Experience Questionnaire From Baseline to Treatment Termination | Constipation | 0 percentage change |
| Low Dose Magnesium Oxide (800 mg/Day) | The Change of Severity of Symptoms as Measured the Symptom Experience Questionnaire From Baseline to Treatment Termination | Abnormal Sweating | 10 percentage change |
| Low Dose Magnesium Oxide (800 mg/Day) | The Change of Severity of Symptoms as Measured the Symptom Experience Questionnaire From Baseline to Treatment Termination | Negative mood change | 0 percentage change |
| Low Dose Magnesium Oxide (800 mg/Day) | The Change of Severity of Symptoms as Measured the Symptom Experience Questionnaire From Baseline to Treatment Termination | Dizziness | 0 percentage change |
| Low Dose Magnesium Oxide (800 mg/Day) | The Change of Severity of Symptoms as Measured the Symptom Experience Questionnaire From Baseline to Treatment Termination | Distress | 10 percentage change |
| Low Dose Magnesium Oxide (800 mg/Day) | The Change of Severity of Symptoms as Measured the Symptom Experience Questionnaire From Baseline to Treatment Termination | Stomach Pain | 0 percentage change |
| Low Dose Magnesium Oxide (800 mg/Day) | The Change of Severity of Symptoms as Measured the Symptom Experience Questionnaire From Baseline to Treatment Termination | Decreased Appetite | 0 percentage change |
| Low Dose Magnesium Oxide (800 mg/Day) | The Change of Severity of Symptoms as Measured the Symptom Experience Questionnaire From Baseline to Treatment Termination | Trouble Concentrating | 0 percentage change |
| High Dose Magnesium Oxide (1200 mg/Day) | The Change of Severity of Symptoms as Measured the Symptom Experience Questionnaire From Baseline to Treatment Termination | Trouble Sleeping | 40 percentage change |
| High Dose Magnesium Oxide (1200 mg/Day) | The Change of Severity of Symptoms as Measured the Symptom Experience Questionnaire From Baseline to Treatment Termination | Stomach Pain | 0 percentage change |
| High Dose Magnesium Oxide (1200 mg/Day) | The Change of Severity of Symptoms as Measured the Symptom Experience Questionnaire From Baseline to Treatment Termination | Diarrhea | -5 percentage change |
| High Dose Magnesium Oxide (1200 mg/Day) | The Change of Severity of Symptoms as Measured the Symptom Experience Questionnaire From Baseline to Treatment Termination | Nausea | 0 percentage change |
| High Dose Magnesium Oxide (1200 mg/Day) | The Change of Severity of Symptoms as Measured the Symptom Experience Questionnaire From Baseline to Treatment Termination | Dizziness | 0 percentage change |
| High Dose Magnesium Oxide (1200 mg/Day) | The Change of Severity of Symptoms as Measured the Symptom Experience Questionnaire From Baseline to Treatment Termination | Decreased Appetite | 0 percentage change |
| High Dose Magnesium Oxide (1200 mg/Day) | The Change of Severity of Symptoms as Measured the Symptom Experience Questionnaire From Baseline to Treatment Termination | Fatigue | 0 percentage change |
| High Dose Magnesium Oxide (1200 mg/Day) | The Change of Severity of Symptoms as Measured the Symptom Experience Questionnaire From Baseline to Treatment Termination | Muscle Weakness | 0 percentage change |
| High Dose Magnesium Oxide (1200 mg/Day) | The Change of Severity of Symptoms as Measured the Symptom Experience Questionnaire From Baseline to Treatment Termination | Abnormal Sweating | 10 percentage change |
| High Dose Magnesium Oxide (1200 mg/Day) | The Change of Severity of Symptoms as Measured the Symptom Experience Questionnaire From Baseline to Treatment Termination | Constipation | 0 percentage change |
| High Dose Magnesium Oxide (1200 mg/Day) | The Change of Severity of Symptoms as Measured the Symptom Experience Questionnaire From Baseline to Treatment Termination | Muscle/Joint Aches | 10 percentage change |
| High Dose Magnesium Oxide (1200 mg/Day) | The Change of Severity of Symptoms as Measured the Symptom Experience Questionnaire From Baseline to Treatment Termination | Negative mood change | 0 percentage change |
| High Dose Magnesium Oxide (1200 mg/Day) | The Change of Severity of Symptoms as Measured the Symptom Experience Questionnaire From Baseline to Treatment Termination | Trouble Concentrating | 0 percentage change |
| High Dose Magnesium Oxide (1200 mg/Day) | The Change of Severity of Symptoms as Measured the Symptom Experience Questionnaire From Baseline to Treatment Termination | Distress | 20 percentage change |
| Placebo | The Change of Severity of Symptoms as Measured the Symptom Experience Questionnaire From Baseline to Treatment Termination | Trouble Concentrating | 0 percentage change |
| Placebo | The Change of Severity of Symptoms as Measured the Symptom Experience Questionnaire From Baseline to Treatment Termination | Muscle/Joint Aches | 0 percentage change |
| Placebo | The Change of Severity of Symptoms as Measured the Symptom Experience Questionnaire From Baseline to Treatment Termination | Decreased Appetite | 0 percentage change |
| Placebo | The Change of Severity of Symptoms as Measured the Symptom Experience Questionnaire From Baseline to Treatment Termination | Dizziness | 0 percentage change |
| Placebo | The Change of Severity of Symptoms as Measured the Symptom Experience Questionnaire From Baseline to Treatment Termination | Trouble Sleeping | 10 percentage change |
| Placebo | The Change of Severity of Symptoms as Measured the Symptom Experience Questionnaire From Baseline to Treatment Termination | Nausea | 0 percentage change |
| Placebo | The Change of Severity of Symptoms as Measured the Symptom Experience Questionnaire From Baseline to Treatment Termination | Stomach Pain | 0 percentage change |
| Placebo | The Change of Severity of Symptoms as Measured the Symptom Experience Questionnaire From Baseline to Treatment Termination | Negative mood change | 0 percentage change |
| Placebo | The Change of Severity of Symptoms as Measured the Symptom Experience Questionnaire From Baseline to Treatment Termination | Diarrhea | 0 percentage change |
| Placebo | The Change of Severity of Symptoms as Measured the Symptom Experience Questionnaire From Baseline to Treatment Termination | Abnormal Sweating | 10 percentage change |
| Placebo | The Change of Severity of Symptoms as Measured the Symptom Experience Questionnaire From Baseline to Treatment Termination | Muscle Weakness | 0 percentage change |
| Placebo | The Change of Severity of Symptoms as Measured the Symptom Experience Questionnaire From Baseline to Treatment Termination | Distress | 10 percentage change |
| Placebo | The Change of Severity of Symptoms as Measured the Symptom Experience Questionnaire From Baseline to Treatment Termination | Constipation | 0 percentage change |
| Placebo | The Change of Severity of Symptoms as Measured the Symptom Experience Questionnaire From Baseline to Treatment Termination | Fatigue | 0 percentage change |
Secondary
The Intra-patient Changes of Magnesium Level From Baseline to the End of Treatment Period Between Magnesium Oxide and Placebo Arms.
The intra-patient changes of magnesium level from baseline to the end of treatment period between magnesium oxide and placebo arms will be compared using a repeated measures model. Serum magnesium concentrations will be performed prior to study medication usage and during the last week of blinded study use. These will be obtained in the first 150 patients. Mean change in serum magnesium concentrations will be compared between the 3 study arms to determine whether there are any apparent changes in the patients receiving placebos vs the two magnesium doses.
Time frame: Baseline to week 8
Population: All patients that started protocol treatment and had serum magnesium levels obtained at baseline and week 9 were included in this analysis.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Low Dose Magnesium Oxide (800 mg/Day) | The Intra-patient Changes of Magnesium Level From Baseline to the End of Treatment Period Between Magnesium Oxide and Placebo Arms. | 0.0 mg/dL | Standard Deviation 0.2 |
| High Dose Magnesium Oxide (1200 mg/Day) | The Intra-patient Changes of Magnesium Level From Baseline to the End of Treatment Period Between Magnesium Oxide and Placebo Arms. | 0.1 mg/dL | Standard Deviation 0.2 |
| Placebo | The Intra-patient Changes of Magnesium Level From Baseline to the End of Treatment Period Between Magnesium Oxide and Placebo Arms. | 0.0 mg/dL | Standard Deviation 0.2 |
p-value: 0.47Kruskal-Wallis
p-value: 0.09Kruskal-Wallis
Secondary
Weekly Frequency of Hot Flashes as Measured by the Hot Flash Diary During the Treatment Period
As part of the Hot Flash Diary, the number of hot flashes was recorded for each patient for each week. For this endpoint, the mean number of hot flashes for each group is reported. A repeated measure analysis comparing each dose level group and the Placebo is reported.
Time frame: Baseline to Week 8
Population: All patients that began protocol treatment and completed the Hot Flash Diary were included in this analysis.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Low Dose Magnesium Oxide (800 mg/Day) | Weekly Frequency of Hot Flashes as Measured by the Hot Flash Diary During the Treatment Period | Week 3 | 6.73 number of hot flashes | Standard Deviation 4.41 |
| Low Dose Magnesium Oxide (800 mg/Day) | Weekly Frequency of Hot Flashes as Measured by the Hot Flash Diary During the Treatment Period | Week 8 | 6.61 number of hot flashes | Standard Deviation 4.58 |
| Low Dose Magnesium Oxide (800 mg/Day) | Weekly Frequency of Hot Flashes as Measured by the Hot Flash Diary During the Treatment Period | Week 5 | 6.31 number of hot flashes | Standard Deviation 4.7 |
| Low Dose Magnesium Oxide (800 mg/Day) | Weekly Frequency of Hot Flashes as Measured by the Hot Flash Diary During the Treatment Period | Week 4 | 6.39 number of hot flashes | Standard Deviation 4.51 |
| Low Dose Magnesium Oxide (800 mg/Day) | Weekly Frequency of Hot Flashes as Measured by the Hot Flash Diary During the Treatment Period | Baseline | 8.48 number of hot flashes | Standard Deviation 4.34 |
| Low Dose Magnesium Oxide (800 mg/Day) | Weekly Frequency of Hot Flashes as Measured by the Hot Flash Diary During the Treatment Period | Week 7 | 6.43 number of hot flashes | Standard Deviation 4.68 |
| Low Dose Magnesium Oxide (800 mg/Day) | Weekly Frequency of Hot Flashes as Measured by the Hot Flash Diary During the Treatment Period | Week 2 | 7.12 number of hot flashes | Standard Deviation 4.18 |
| Low Dose Magnesium Oxide (800 mg/Day) | Weekly Frequency of Hot Flashes as Measured by the Hot Flash Diary During the Treatment Period | Week 1 | 7.83 number of hot flashes | Standard Deviation 4.34 |
| Low Dose Magnesium Oxide (800 mg/Day) | Weekly Frequency of Hot Flashes as Measured by the Hot Flash Diary During the Treatment Period | Week 6 | 6.34 number of hot flashes | Standard Deviation 4.56 |
| High Dose Magnesium Oxide (1200 mg/Day) | Weekly Frequency of Hot Flashes as Measured by the Hot Flash Diary During the Treatment Period | Week 4 | 5.34 number of hot flashes | Standard Deviation 3.76 |
| High Dose Magnesium Oxide (1200 mg/Day) | Weekly Frequency of Hot Flashes as Measured by the Hot Flash Diary During the Treatment Period | Baseline | 7.55 number of hot flashes | Standard Deviation 3.89 |
| High Dose Magnesium Oxide (1200 mg/Day) | Weekly Frequency of Hot Flashes as Measured by the Hot Flash Diary During the Treatment Period | Week 1 | 7.15 number of hot flashes | Standard Deviation 4.13 |
| High Dose Magnesium Oxide (1200 mg/Day) | Weekly Frequency of Hot Flashes as Measured by the Hot Flash Diary During the Treatment Period | Week 2 | 6.51 number of hot flashes | Standard Deviation 4.19 |
| High Dose Magnesium Oxide (1200 mg/Day) | Weekly Frequency of Hot Flashes as Measured by the Hot Flash Diary During the Treatment Period | Week 3 | 5.87 number of hot flashes | Standard Deviation 4.21 |
| High Dose Magnesium Oxide (1200 mg/Day) | Weekly Frequency of Hot Flashes as Measured by the Hot Flash Diary During the Treatment Period | Week 5 | 5.15 number of hot flashes | Standard Deviation 4 |
| High Dose Magnesium Oxide (1200 mg/Day) | Weekly Frequency of Hot Flashes as Measured by the Hot Flash Diary During the Treatment Period | Week 6 | 4.95 number of hot flashes | Standard Deviation 4.04 |
| High Dose Magnesium Oxide (1200 mg/Day) | Weekly Frequency of Hot Flashes as Measured by the Hot Flash Diary During the Treatment Period | Week 7 | 4.92 number of hot flashes | Standard Deviation 4.13 |
| High Dose Magnesium Oxide (1200 mg/Day) | Weekly Frequency of Hot Flashes as Measured by the Hot Flash Diary During the Treatment Period | Week 8 | 4.88 number of hot flashes | Standard Deviation 4.02 |
| Placebo | Weekly Frequency of Hot Flashes as Measured by the Hot Flash Diary During the Treatment Period | Week 2 | 7.26 number of hot flashes | Standard Deviation 4.65 |
| Placebo | Weekly Frequency of Hot Flashes as Measured by the Hot Flash Diary During the Treatment Period | Baseline | 8.89 number of hot flashes | Standard Deviation 4.52 |
| Placebo | Weekly Frequency of Hot Flashes as Measured by the Hot Flash Diary During the Treatment Period | Week 6 | 6.37 number of hot flashes | Standard Deviation 4.3 |
| Placebo | Weekly Frequency of Hot Flashes as Measured by the Hot Flash Diary During the Treatment Period | Week 1 | 8.04 number of hot flashes | Standard Deviation 4.59 |
| Placebo | Weekly Frequency of Hot Flashes as Measured by the Hot Flash Diary During the Treatment Period | Week 8 | 6.38 number of hot flashes | Standard Deviation 4.67 |
| Placebo | Weekly Frequency of Hot Flashes as Measured by the Hot Flash Diary During the Treatment Period | Week 4 | 6.73 number of hot flashes | Standard Deviation 4.44 |
| Placebo | Weekly Frequency of Hot Flashes as Measured by the Hot Flash Diary During the Treatment Period | Week 3 | 6.97 number of hot flashes | Standard Deviation 4.82 |
| Placebo | Weekly Frequency of Hot Flashes as Measured by the Hot Flash Diary During the Treatment Period | Week 7 | 6.18 number of hot flashes | Standard Deviation 4.23 |
| Placebo | Weekly Frequency of Hot Flashes as Measured by the Hot Flash Diary During the Treatment Period | Week 5 | 6.45 number of hot flashes | Standard Deviation 4.33 |
p-value: 0.25ANOVA
p-value: 0.55ANOVA